News & Updates

Niraparib-abiraterone-prednisone combo improves multiple outcomes in HRR+ mCRPC
Niraparib-abiraterone-prednisone combo improves multiple outcomes in HRR+ mCRPC
04 Mar 2022 byRoshini Claire Anthony

In patients with metastatic castration-resistant prostate cancer (mCRPC) with homologous recombination repair (HRR) gene alterations*, combining niraparib with abiraterone acetate plus prednisone (AAP) in the first-line setting improved radiographic progression-free survival (rPFS) and other outcomes, results of the phase III MAGNITUDE study showed.

Niraparib-abiraterone-prednisone combo improves multiple outcomes in HRR+ mCRPC
04 Mar 2022
Stigma hurts mental health of COVID-19 survivors
Stigma hurts mental health of COVID-19 survivors
04 Mar 2022

Survivors of the coronavirus disease 2019 (COVID-19) face social stigma when they return to their communities. Such stigma appears to harm mental health, reports a recent study.

Stigma hurts mental health of COVID-19 survivors
04 Mar 2022